<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05047458</url>
  </required_header>
  <id_info>
    <org_study_id>ACH228-001</org_study_id>
    <secondary_id>ACTRN12617001521314</secondary_id>
    <secondary_id>U1111-1203-1371</secondary_id>
    <nct_id>NCT05047458</nct_id>
  </id_info>
  <brief_title>A Study of Single-dose ALXN2050 in Healthy Adults</brief_title>
  <official_title>A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACH-0145228 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Achillion, a wholly owned subsidiary of Alexion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a phase 1, first-in-human, single-center, randomized, double-blind (participants and&#xD;
      investigator blind, sponsor open) placebo-controlled, single-ascending dose study of&#xD;
      ACH-0145228 (ALXN2050) conducted in healthy adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2017</start_date>
  <completion_date type="Actual">April 13, 2018</completion_date>
  <primary_completion_date type="Actual">April 13, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number Of Participants Experiencing Serious Adverse Events</measure>
    <time_frame>Day 1 through Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number Of Participants Experiencing Grade 3 Or 4 Adverse Events (AEs)</measure>
    <time_frame>Day 1 through Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number Of Participants Experiencing AEs Leading To Discontinuation From The Study</measure>
    <time_frame>Day 1 through Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number Of Participants Experiencing Grade 3 Or 4 Laboratory Abnormalities</measure>
    <time_frame>Day 1 through Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number Of Participants Experiencing Treatment-emergent Vital Signs, Physical Examination Results, And Electrocardiogram (ECG) Abnormalities</measure>
    <time_frame>Day 1 through Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) Of ALXN2050</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Reach The Maximum Plasma Concentration (Tmax) Of ALXN2050</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under The Plasma Concentration-time Curve Extrapolated To Infinity (AUC0-inf) Of ALXN2050</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alternative Pathway (AP) Activity As Measured By Wieslab Assay</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Bb Fragment Of Complement Factor B Concentration Over Time</measure>
    <time_frame>Up to 144 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: 40 mg ALXN2050/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive ALXN2050 or placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: 80 mg ALXN2050/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive ALXN2050 or placebo on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3: 120 mg ALXN2050/Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to receive ALXN2050 or placebo on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN2050</intervention_name>
    <description>Powder-in-capsule (PIC).</description>
    <arm_group_label>Cohort 1: 40 mg ALXN2050/Placebo</arm_group_label>
    <arm_group_label>Cohort 2: 80 mg ALXN2050/Placebo</arm_group_label>
    <arm_group_label>Cohort 3: 120 mg ALXN2050/Placebo</arm_group_label>
    <other_name>ACH-0145228 (formerly)</other_name>
    <other_name>ACH-5228</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>PIC.</description>
    <arm_group_label>Cohort 1: 40 mg ALXN2050/Placebo</arm_group_label>
    <arm_group_label>Cohort 2: 80 mg ALXN2050/Placebo</arm_group_label>
    <arm_group_label>Cohort 3: 120 mg ALXN2050/Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Healthy was defined as having no clinically relevant abnormalities identified by a&#xD;
             detailed medical history, physical examination, blood pressure and heart rate&#xD;
             measurements, 12-lead ECG, and clinical laboratory tests.&#xD;
&#xD;
          -  Had a body mass index of 18 to 30 kilograms (kg)/meter squared with a minimum body&#xD;
             weight of 50 kg.&#xD;
&#xD;
          -  Female participant of nonchildbearing potential.&#xD;
&#xD;
          -  Male participant agreed to abstinence or use of a highly effective form of&#xD;
             contraception.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Had a history or clinically relevant evidence of significant cardiovascular,&#xD;
             pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic,&#xD;
             dermatologic, neurological, or psychiatric disease.&#xD;
&#xD;
          -  Had any condition possibly affecting drug absorption.&#xD;
&#xD;
          -  Had a body temperature greater than or equal to 38Â°Celsius on Day -1 or Day 1, Hour 0;&#xD;
             had a history of febrile illness, or other evidence of infection, within 14 days prior&#xD;
             to first study drug administration.&#xD;
&#xD;
          -  Had a positive urine drug screen at Screening or Day -1; was a current&#xD;
             tobacco/nicotine user or smoker; had consumed any alcohol within 72 hours before first&#xD;
             study drug administration or had a history of regular alcohol consumption within 6&#xD;
             months of Screening.&#xD;
&#xD;
          -  Had participated in a clinical study within 30 days prior to first study drug&#xD;
             administration&#xD;
&#xD;
          -  Had clinically significant laboratory abnormalities,&#xD;
&#xD;
          -  Had donated blood or lost more than 500 milliliters of blood within 3 months prior to&#xD;
             first study drug administration; had received a blood transfusion or blood products&#xD;
             within 6 months prior to first study drug administration.&#xD;
&#xD;
          -  Had a clinically significant history of drug allergy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 9, 2021</study_first_submitted>
  <study_first_submitted_qc>September 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 17, 2021</study_first_posted>
  <last_update_submitted>September 9, 2021</last_update_submitted>
  <last_update_submitted_qc>September 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Factor D Inhibitor</keyword>
  <keyword>Complement</keyword>
  <keyword>ALXN2050</keyword>
  <keyword>ACH-0145228</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Safety</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

